CA3132385A1 - Il-10 variant molecules and methods of treating inflammatory disease and oncology - Google Patents

Il-10 variant molecules and methods of treating inflammatory disease and oncology Download PDF

Info

Publication number
CA3132385A1
CA3132385A1 CA3132385A CA3132385A CA3132385A1 CA 3132385 A1 CA3132385 A1 CA 3132385A1 CA 3132385 A CA3132385 A CA 3132385A CA 3132385 A CA3132385 A CA 3132385A CA 3132385 A1 CA3132385 A1 CA 3132385A1
Authority
CA
Canada
Prior art keywords
fusion protein
variant
seq
antibody
ebv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3132385A
Other languages
English (en)
French (fr)
Inventor
John Mumm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deka Biosciences Inc
Original Assignee
Deka Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deka Biosciences Inc filed Critical Deka Biosciences Inc
Publication of CA3132385A1 publication Critical patent/CA3132385A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3132385A 2019-03-06 2020-03-06 Il-10 variant molecules and methods of treating inflammatory disease and oncology Pending CA3132385A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962814669P 2019-03-06 2019-03-06
US62/814,669 2019-03-06
US201962899504P 2019-09-12 2019-09-12
US62/899,504 2019-09-12
US202062962332P 2020-01-17 2020-01-17
US62/962,332 2020-01-17
PCT/US2020/021498 WO2020181235A1 (en) 2019-03-06 2020-03-06 Il-10 variant molecules and methods of treating inflammatory disease and oncology

Publications (1)

Publication Number Publication Date
CA3132385A1 true CA3132385A1 (en) 2020-09-10

Family

ID=72334859

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3132385A Pending CA3132385A1 (en) 2019-03-06 2020-03-06 Il-10 variant molecules and methods of treating inflammatory disease and oncology

Country Status (7)

Country Link
US (8) US10858412B2 (enExample)
EP (1) EP3934681A4 (enExample)
JP (2) JP2022524018A (enExample)
KR (1) KR20210139312A (enExample)
CN (2) CN121652287A (enExample)
CA (1) CA3132385A1 (enExample)
WO (1) WO2020181235A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220378946A1 (en) * 2021-05-28 2022-12-01 Iucf-Hyu (Industry-University Cooperation Foundation Hanyang University) Cell penetrating peptides and uses thereof

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10017739B2 (en) * 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
WO2020212598A1 (en) 2019-04-19 2020-10-22 Synerkine Pharma B.V. A fusion protein comprising il13
IL298136A (en) 2020-05-13 2023-01-01 Bonum Therapeutics Inc Preparations of protein complexes and methods of using them
CA3186753A1 (en) 2020-07-20 2022-01-27 John Mumm Dual cytokine fusion proteins comprising il-10
CN112898436A (zh) * 2020-10-23 2021-06-04 广州医科大学附属肿瘤医院 一种具有靶向功能的鼠pd1和鼠il-15基因融合蛋白的表达及其应用
WO2023078245A1 (zh) * 2021-11-02 2023-05-11 广东菲鹏制药股份有限公司 Il10单体融合蛋白及其应用
WO2023114775A2 (en) * 2021-12-13 2023-06-22 Deka Biosciences, Inc. Dual cytokine fusion proteins comprising multi-subunit cytokines
US20230210953A1 (en) * 2021-12-16 2023-07-06 Deka Biosciences, Inc. Use of dual cytokine fusion proteins comprising il-10 and adoptive cell therapies or bispecific t-cell engagers to treat cancer
CA3244604A1 (en) 2022-02-22 2023-08-31 Deka Biosciences, Inc. METHOD FOR REDUCING A BISPECIFIC T LYMPHOCYTE RECRUITER OR A CHIMERICAL ANTIGEN RECEPTOR T LYMPHOCYTE CYTOKINE RELEASE SYNDROME USING INTERLEUKIN 4 OR 10, OR AN ASSOCIATED FUSION PROTEIN
CN114632156B (zh) * 2022-05-17 2022-08-16 中国人民解放军军事科学院军事医学研究院 Tim-3在预防、治疗或减轻疼痛中的应用
WO2024097875A1 (en) * 2022-11-02 2024-05-10 Shattuck Labs, Inc. Fusion proteins for the treatment of nonalcoholic steatohepatitis
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法
WO2025110822A1 (ko) * 2023-11-24 2025-05-30 주식회사 메드팩토 피브로넥틴 엑스트라도메인 b (extradomain b of fibronectin, edb-fn) 및 전환성장인자 베타(transforming growth factor β, tgfβ)에 특이적으로 결합하는 융합 단백질 및 이의 용도
CN121108363A (zh) * 2024-06-12 2025-12-12 广东菲鹏制药股份有限公司 一种融合蛋白及其用途
CN119613546B (zh) * 2025-02-10 2025-05-13 细胞生态海河实验室 Il-10抗体及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2648484A1 (en) * 2006-05-08 2007-11-15 Philogen Spa Antibody-targeted cytokines for therapy
CN101868246A (zh) * 2007-09-21 2010-10-20 加利福尼亚大学董事会 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
DK3281952T3 (da) * 2007-10-30 2020-08-03 Philogen Spa Antigen, der er forbundet med reumatoid artritis
NO2344540T3 (enExample) * 2008-10-02 2018-04-28
WO2012045334A1 (en) * 2010-10-05 2012-04-12 Synthon Bv Biologically active il-10 fusion proteins
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
PE20150645A1 (es) 2012-08-08 2015-05-11 Roche Glycart Ag Proteinas de fusion de interleuquina 10 y usos de las mismas
ES2743423T3 (es) * 2012-10-03 2020-02-19 Philogen Spa Conjugado de anticuerpos para su uso en el tratamiento de una enfermedad inflamatoria intestinal
PE20151893A1 (es) 2013-03-14 2015-12-30 Parkash Gill Tratamiento del cancer usando anticuerpos que se unen a grp78 en la superficie celular
WO2015117930A1 (en) * 2014-02-06 2015-08-13 F. Hoffmann-La Roche Ag Interleukine 10 immunoconjugates
CN104403004B (zh) * 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
AU2015364396B2 (en) * 2014-12-19 2018-08-09 Alkermes, Inc. Single chain Fc fusion proteins
WO2017091611A1 (en) * 2015-11-23 2017-06-01 Immungene, Inc Enhanced cancer immunotherapy using antibody-interferon fusion molecules
RU2018124307A (ru) * 2015-12-04 2020-01-14 Новартис Аг Антительно-цитокиновые привитые композиции и способы применения для иммунорегуляции

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220378946A1 (en) * 2021-05-28 2022-12-01 Iucf-Hyu (Industry-University Cooperation Foundation Hanyang University) Cell penetrating peptides and uses thereof
US12576162B2 (en) * 2021-05-28 2026-03-17 Iucf-Hyu (Industry-University Cooperation Foundation Hanyang University) Cell penetrating peptides and uses thereof

Also Published As

Publication number Publication date
CN121652287A (zh) 2026-03-13
US20240294591A1 (en) 2024-09-05
US10975134B2 (en) 2021-04-13
CN114072164A (zh) 2022-02-18
JP2026016505A (ja) 2026-02-03
KR20210139312A (ko) 2021-11-22
US20200385436A1 (en) 2020-12-10
US20210040168A1 (en) 2021-02-11
WO2020181235A1 (en) 2020-09-10
JP2022524018A (ja) 2022-04-27
US10858412B2 (en) 2020-12-08
US20200283488A1 (en) 2020-09-10
US10981965B2 (en) 2021-04-20
EP3934681A4 (en) 2023-12-20
US20200399337A1 (en) 2020-12-24
EP3934681A1 (en) 2022-01-12
US10981966B2 (en) 2021-04-20
US20200385437A1 (en) 2020-12-10
US20200385435A1 (en) 2020-12-10
US10975133B2 (en) 2021-04-13
US20220106373A1 (en) 2022-04-07

Similar Documents

Publication Publication Date Title
US20240294591A1 (en) Il-10 variant molecules and methods for treating inflammatory disease and oncology
US12145007B2 (en) Dual cytokine fusion proteins comprising IL-10
US20240409600A1 (en) Dual cytokine fusion proteins comprising multi-subunit cytokines
US20260125435A1 (en) Il-10 variant molecules and methods for treating inflammatory disease and oncology
RU2836849C2 (ru) Вариантные молекулы il-10 и способ лечения злокачественной опухоли

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240229

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250221

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250221

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250221

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20250718

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250806

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251204

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260119

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260119

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260119

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260224

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260224